Overview
- In the ATTAIN-2 double-blind, randomized trial, roughly 1,500–1,600 adults with obesity and type 2 diabetes across 136 sites in 10 countries took daily orforglipron or placebo for 72 weeks.
- Weight loss was dose dependent: about 5–5.5% at 6 mg, 7–7.8% at 12 mg, and 9.6–10.5% at 36 mg, versus roughly 2.2–2.5% with placebo.
- At the highest dose, average HbA1c fell by nearly 2 percentage points, with about 75% of participants reaching commonly targeted glucose levels.
- Side effects were predominantly mild to moderate gastrointestinal symptoms consistent with GLP‑1 drugs, with higher discontinuation at medium and high doses at around 10%.
- As a small‑molecule pill, orforglipron requires no refrigeration or food/water timing and may be cheaper to produce and distribute, though average weight loss trails tirzepatide and appears roughly comparable to semaglutide in people with diabetes; the Eli Lilly–funded results were published in The Lancet.